Provider Alerts Archive: 2024
Alert Archives:
Filter:
- All
- Blue Cross commercial
- Medicare Plus Blue
- BCN commercial
- BCN Advantage
December 2024
Generic pemetrexed to require prior authorization for most members starting Jan. 1 ![]()
Steqeyma to require prior authorization for most members ![]()
Online behavioral health care navigation solution to end March 2025 ![]()
Enzyme replacement therapy drugs to have a quantity limit requirement for most commercial members ![]()
Questionnaire updates in the e-referral system effective Dec. 22 ![]()
December – January holiday closure: How to submit authorization requests for inpatient admissions ![]()
e-referral system out of service for maintenance overnight December 21-22 ![]()
Starting Feb. 1, 2025, Cimzia will change to nonpreferred on our prescription drug plans ![]()
Beqvez and Kebilidi will have additional requirements for most commercial members starting Jan. 27 ![]()
Until Dec. 22, fax requests for prospective inpatient admissions with procedure code *99222 ![]()
Yesintek to require prior authorization for most members ![]()
More information about the Oncology Value Management program through OncoHealth ![]()
November 2024
Questionnaires removed from the e-referral system on Nov. 24 ![]()
Nov. 28-29 holiday closure: How to submit authorization requests for inpatient admissions ![]()
Kebilidi to require prior authorization for most members ![]()
Aucatzyl IV to require prior authorization for most members starting Nov. 21 ![]()
e-referral system out of service for maintenance overnight November 16-17 ![]()
October 2024
Nov. 5 holiday closure: How to submit authorization requests for inpatient admissions ![]()
Hympavzi and Imuldosa to have a prior authorization requirement for most members ![]()
BAHA (Bone-anchored hearing aid) questionnaire removed from the e-referral system ![]()
We changed how we manage immunoglobulin therapies for most commercial members starting Oct. 1 ![]()
Prior authorization approvals now valid for 180 days for PTs and OTs in Category A ![]()
e-referral system out of service for maintenance overnight October 19-20 ![]()
You can now add comments when answering InterQual Connect questions in the e-referral system ![]()
Tremfya IV will require prior authorization for Medicare Advantage members starting Dec. 2 ![]()
Otulfi to have a prior authorization requirement for most members ![]()
Register now for Oct. 10 webinar on prior authorization programs with Carelon ![]()
Select a recommended procedure when answering InterQual Connect questions in the e-referral system ![]()
September 2024
Updated forms now available for submitting prior authorization requests for post-acute care services ![]()
Tezspire to have a site-of-care requirement for most commercial members starting Jan. 1 ![]()
Changes to the Breast Elastography Trigger questionnaire in the e-referral system ![]()
2025 coverage change for GLP-1 drugs to treat obesity ![]()
Preferred product for Hemgenix for most commercial members starting Nov. 11 ![]()
Ocrevus Zunovo SC to have requirements for most commercial members starting Oct. 3 ![]()
Update: Tremfya IV to require prior authorization for most commercial members starting Sept. 26 ![]()
e-referral system out of service for maintenance overnight September 21-22 ![]()
Jubbonti and Wezlana to require prior authorization for Medicare Advantage members starting Nov. 3 ![]()
Rituximab preferred agents to change for Medicare Advantage members starting Jan. 1 ![]()
August 2024
Pavblu to require prior authorization for most commercial members starting Sept. 5 ![]()
Sept. 2 holiday closure: How to submit authorization requests for inpatient admissions ![]()
Niktimvo IV to require prior authorization for most commercial members starting Sept. 5 ![]()
Zynyz and Talvey to require prior authorization for URMBT members with Blue Cross non-Medicare plans ![]()
Enzeevu to require prior authorization for most commercial members starting Aug. 29 ![]()
PiaSky and Tecelra will require prior authorization for Medicare Advantage members starting Oct. 1 ![]()
e-referral system out of service for maintenance overnight August 17-18 ![]()
Physician appointment access survey in process ![]()
Tecelra to require prior authorization for most commercial members starting Aug. 15 ![]()
July 2024
Preferred immune globulin products for Medicare Advantage members to change starting Nov. 1 ![]()
Rytelo to require prior authorization for most commercial members starting Aug. 8 ![]()
Update: Changes coming for select weight loss drugs for some commercial members ![]()
Blue Cross Behavioral Health no longer requires autism diagnostic re-evaluations ![]()
Guidelines for billing Avastin for Blue Cross and BCN commercial members ![]()
Epysqli to require prior authorization for most commercial members starting Aug. 8 ![]()
Changes to the BCN referral and authorization requirements for Michigan providers document ![]()
Rytelo will require prior authorization for Medicare Advantage members starting Aug. 1 ![]()
Updated TurningPoint medical policies for musculoskeletal and pain management procedures ![]()
Kisunla to require prior authorization for most commercial members starting July 18 ![]()
e-referral system unavailable on two weekends in July ![]()
We’re changing how we manage immunoglobulin therapies for most commercial members starting Oct. 1 ![]()
June 2024
Yimmugo and Piasky to require prior authorization for most commercial members starting July 11 ![]()
July 4-5 holiday closure: How to submit authorization requests for inpatient admissions ![]()
Utilization management phone closed on June 28 until 1 p.m. ![]()
Questionnaire changes in the e-referral system starting June 23 ![]()
Lamzede and Vyjuvek to have requirements for URMBT members with Blue Cross non-Medicare plans ![]()
June 19 holiday closure: How to submit authorization requests for inpatient admissions ![]()
e-referral system out of service for maintenance overnight June 15-16 ![]()
Beqvez will have additional requirements for most commercial members ![]()
Vyjuvek will have additional requirements for most commercial members starting July 22 ![]()
Bkemv to require prior authorization for most commercial members starting June 13 ![]()
Alyglo has requirements for Federal Employee Program non-Medicare members as of June 1 ![]()
Update: Changes coming for select weight loss drugs for some commercial members ![]()
Soliris and Ultomiris to have a step therapy requirement for commercial members ![]()
May 2024
Opuviz and Yesafili to require prior authorization for most commercial members starting June 6 ![]()
Medicare implantable ambulatory event monitors questionnaire removed from the e-referral system ![]()
Hemlibra to have a quantity limit requirement for most commercial members ![]()
Changes to the Hyperbaric oxygen therapy questionnaires in the e-referral system ![]()
Step therapy requirement added for Saphnelo for Medicare Advantage members starting Sept. 1 ![]()
May 27 holiday closure: How to submit authorization requests for inpatient admissions ![]()
New information about Winrevair SC for commercial members ![]()
We’ll use 2024 InterQual criteria starting Aug. 1 ![]()
Loqtorzi to have requirements for most members starting Aug. 15 ![]()
Beqvez will require prior authorization for Medicare Advantage
members starting June 1 ![]()
e-referral system unavailable on two weekends in May ![]()
Step therapy requirement added for botulinum toxins for Medicare Advantage members starting Aug. 5 ![]()
Update: Beqvez to require prior authorization for most commercial members starting May 9 ![]()
April 2024
Pemfexy and Pemrydi RTU to have additional step therapy requirements for most members ![]()
Hercessi to require prior authorization for most commercial members starting May 16 ![]()
Save time: Submit only required information about inpatient acute care medical / surgical admissions ![]()
Additional drugs to have a site-of-care requirement for some commercial members, starting Aug. 1 ![]()
Guidelines for using the Autism diagnostic evaluation results form ![]()
Omvoh SC and IV to have a step therapy requirement for most commercial members starting June 3 ![]()
Update: Spevigo SC to have requirements for most commercial members starting April 25 ![]()
e-referral system out of service for maintenance overnight April 20-21 ![]()
Amtagvi will have additional requirements for most commercial members, starting May 28 ![]()
Procedure codes that require prior authorization through BCN ![]()
Cosentyx IV to have a site-of-care requirement for most commercial members starting July 1 ![]()
Update: Winrevair to require prior authorization for Medicare Advantage members starting May 1 ![]()
Vyjuvek to have a site-of-care requirement for most commercial members starting April 4 ![]()
March 2024
Questionnaire changes in the e-referral system starting March 31 ![]()
March 29 holiday closure: How to submit authorization requests for inpatient admissions ![]()
Lenmeldy to require prior authorization for most commercial
members starting March 28 ![]()
Tofidence will require prior authorization for Medicare Advantage members starting May 1 ![]()
Elrexfio and Talvey to require prior authorization for most members starting June 20 ![]()
Explanation of lifestyle modification for weight loss drugs ![]()
e-referral system out of service for maintenance overnight March 16-17 ![]()
Update: Preferred product for Zynteglo for most commercial members starting April 19 ![]()
Udenyca Onbody to require prior authorization for most commercial members effective immediately ![]()
We’re changing how we manage Entyvio SC and Omvoh SC, starting March 1 ![]()
Additional drugs to require prior authorization for Medicare Advantage members starting April 1 ![]()
February 2024
Medicare Plus Blue PPO Provider Manual update coming in April 2024 ![]()
Update: Prior authorization requests for behavioral health services ![]()
Changes to the Gastric stimulation and Breast reconstruction questionnaires in the e-referral system ![]()
Update: Amtagvi to require prior authorization for most commercial members starting Feb. 29 ![]()
Additional preferred products for Soliris and Ultomiris for most commercial members starting April 1 ![]()
e-referral system out of service for maintenance overnight Feb. 17-18 ![]()
Don’t submit referrals for members with BCN point-of-service plans ![]()
Call Blue Cross Behavioral Health if you need additional ABA units to bill approved authorizations ![]()
January 2024
We’re no longer mailing some letters related to Medicare Advantage inpatient admissions ![]()
Pemfexy to have step therapy requirements starting April 26 ![]()
Omvoh to have a site-of-care requirement for most commercial members starting May 1 ![]()
Updated: Entyvio, Omvoh and Wezlana to require prior authorization for most commercial members ![]()
Questionnaire changes in e-referral starting Jan. 28 ![]()
Starting March 1, some continuous glucose monitor products will require prior authorization ![]()
Updated: Alyglo to require prior authorization for most commercial members starting Jan. 18 ![]()
Cabenuva to have requirements for most commercial members starting May 1 ![]()
Email us if you’re having technical problems using the Blue Cross Behavioral Health provider portal ![]()
e-referral system out of service for maintenance overnight Jan. 20-21 ![]()
Continuity of care arrangements are expanded to Medicare Advantage members ![]()
Requirements changing for some medical benefit drugs for Medicare Advantage members ![]()
Blue Cross Behavioral Health to reinstate requirements; providers can submit authorization requests ![]()
January 2, 2024: Changes to ereferrals.bcbsm.com ![]()
Jan. 15 holiday closure: How to submit authorization requests for inpatient admissions ![]()